SCHEMBL91595

SCHEMBL91595

Cc1cc(C)c(NC(=O)c2nn(C)c3ccccc23)cc1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.58
LCK P06239 1/20 0.52
CSK P41240 1/20 0.52
TSHR P16473 2/20 0.49
ALDH1A1 P00352 1/20 0.49
CYP3A4 P08684 1/20 0.49
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49
HDAC3 O15379 1/20 0.48
HDAC1 Q13547 1/20 0.48
HTR3E A5X5Y0 2/20 0.47
HTR3B O95264 2/20 0.47
HTR3A P46098 2/20 0.47
HTR3D Q70Z44 2/20 0.47
HTR3C Q8WXA8 2/20 0.47
SLC22A2 O15244 1/20 0.47
CHRNB2 P17787 1/20 0.47
CHRNA3 P32297 1/20 0.47
CHRNA4 P43681 1/20 0.47
KCNH2 Q12809 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL91588 0.90 KDM4E (0.53) KDM4ELCKCSKTSHRALDH1A1
SCHEMBL91590 0.87 ALDH1A1 (0.55) KDM4ELCKCSKTSHRALDH1A1
SCHEMBL92358 0.83 KDM4E (0.53) KDM4ELCKCSKTSHRALDH1A1
SCHEMBL92552 0.83 KDM4E (0.53) KDM4ELCKCSKTSHRALDH1A1
SCHEMBL12327693 0.81 KDM4E (0.46) KDM4ELCKCSKTSHRALDH1A1
SCHEMBL91600 0.80 SMN1; SMN2 (0.55) KDM4ELCKCSKTSHRALDH1A1
SCHEMBL10273937 0.80 THRB (0.56) KDM4ELCKCSKTSHRALDH1A1
SCHEMBL24004611 0.80 KDM4E (0.59) KDM4ETSHRALDH1A1CYP3A4MAPK1
SCHEMBL14772007 0.80 KDM4E (0.50) KDM4ELCKCSKTSHRALDH1A1
SCHEMBL10273949 0.80 KDM4E (0.50) KDM4ELCKCSKTSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233901-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 KDM4E 1607/4885LCK 4357/4885CSK 4161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.